DTcP-Hib-MCV4 / CanSino - LARVOL DELTA

Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine (clinicaltrials.gov) - P1 | N=260 | Not yet recruiting | Sponsor: CanSino Biologics Inc.

New P1 trial • CNS Disorders • Infectious Disease • Influenza • Meningococcal Infections • Pertussis • Respiratory Diseases • Tetanus

CanSinoBIO Obtained Approval for Clinical Trials on DTcP-Hib-MCV4 Combined Vaccine (CanSinoBIO Press Release) - "CanSino Biologics Inc...is pleased to announce that it has obtained clinical trial approval from the National Medical Products Administration of the People’s Republic of China to initiate a clinical trial for its absorbed diphtheria, tetanus and acellular pertussis (components) (the 'DTcP') Haemophilus Influenzae Type b (Conjugate) (the 'Hib') - Group ACYW135 Meningococcal (Conjugate) (the 'MCV4') combined vaccine (the 'DTcP-Hib-MCV4 Combined Vaccine')...Additionally, the DTcP Infant vaccine is in Phase III clinical trials, and the Hib Vaccine is in Phase I clinical trials...Furthermore, CanSinoBIO is expanding its global innovative vaccine portfolio with its VLP-Polio vaccine, which is currently in Phase Ⅰ/Ⅱ clinical trials in Indonesia."

New trial • Infectious Disease